China Massive Selection for Niraparib Tosylate Hydrate - Captopril – CPF manufacturers and suppliers

Massive Selection for Niraparib Tosylate Hydrate - Captopril – CPF

Short Description:

Product Detail

Product Tags

Feedback (2)

Our enterprise since its inception, constantly regards product good quality as organization life, constantly improve production technology, strengthen merchandise high quality and continuously strengthen enterprise total good quality administration, in strict accordance with all the national standard ISO 9001:2000 for Niraparib Tosylate Hydrate, Doxycycline Mono 100mg Tablet, Pregabalin Manufacturer, We invites you and your company to thrive together with us and share a dazzling foreseeable future in world-wide market place.

Massive Selection for Niraparib Tosylate Hydrate - Captopril – CPF Detail:

Description

Captopril (SQ-14534) is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE).

In Vitro

Captopril (SQ-14534) has been shown to have similar morbidity and mortality benefits to those of diuretics and beta-blockers in hypertensive patients. Captopril (SQ-14534) has been shown to delay the progression of diabetic nephropathy, and enalapril and lisinopril prevent the development of nephropathy in normoalbuminuric patients with diabetes[1]. An equimolar ratio of the cis and trans states of Captopril (SQ-14534) exists in solution and that the enzyme selects only the trans state of the inhibitor that presents architectural and stereoelectronic complementarity with its substrate binding groove[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT03179163	Penn State University\|National Heart, Lung, and Blood Institute (NHLBI)	Hypertension,Essential	July 20, 2016	Phase 1\|Phase 2
NCT03660293	Tanta University	Diabetes Mellitus, Type 1	April 1, 2017	Not Applicable
NCT03147092	Centro Neurológico de Pesquisa e Reabiitação, Brazil	Hypertension\|Blood Pressure	February 1, 2018	Early Phase 1
NCT00252317	Rigshospitalet, Denmark	Aortic Stenosis	November 2005	Phase 4
NCT02217852	West China Hospital	Hypertension	August 2014	Phase 4
NCT01626469	Brigham and Women´s Hospital	Type 2 Diabetes Mellitus	May 2012	Phase 1\|Phase 2
NCT00391846	AstraZeneca	Heart Failure\|Ventricular Dysfunction, Left	October 2006	Phase 4
NCT00240656	Hebei Medical University	Hypertension, Pulmonary	October 2005	Phase 1
NCT00086723	Northwestern University\|National Cancer Institute (NCI)	Unspecified Adult Solid Tumor, Protocol Specific	July 2003	Phase 1\|Phase 2
NCT00663949	Shiraz University of Medical Sciences	Diabetic Nephropathy	February 2006	Phase 2\|Phase 3
NCT01437371	University Hospital, Clermont-Ferrand\|Servier\|LivaNova	Heart Failure	August 2011	Phase 3
NCT04288700	Ain Shams University	Infantile Hemangioma	October 1, 2019	Phase 4
NCT00223717	Vanderbilt University\|Vanderbilt University Medical Center	Hypertension	January 2001	Phase 1
NCT02770378	University of Ulm\|Reliable Cancer Therapies\|Anticancer Fund, Belgium	Glioblastoma	November 2016	Phase 1\|Phase 2
NCT01761916	Instituto Materno Infantil Prof. Fernando Figueira	Preeclampsia	January 2013	Phase 4
NCT01545479	Instituto de Cardiologia do Rio Grande do Sul	Renal Disease	January 2010	Phase 4
NCT00935805	Hospital de Clinicas de Porto Alegre\|Conselho Nacional de Desenvolvimento Científico e Tecnológico\|Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, Brazil	Diabetes Mellitus\|Arterial Hypertension	July 2006
NCT00742040	The Hospital for Sick Children	Heart Disease	August 2008	Phase 2
NCT03613506	Wuhan University	Radiotherapy Side Effect\|Taking Captopril	October 25, 2018	Phase 2
NCT00004230	Northwestern University\|National Cancer Institute (NCI)	Cancer	October 1999	Phase 3
NCT00660309	Novartis	Type 2 Diabetes Mellitus	April 2008	Phase 4
NCT00292162	NHS Greater Glasgow and Clyde	Chronic Heart Failure\|Atrial Fibrillation	January 2007	Not Applicable
NCT01271478	Coordinación de Investigación en Salud, Mexico	Inflammation\|End-stage Renal Disease	August 2009	Phase 4
NCT04193137	Chongqing Medical University	Primary Aldosteronism	November 30, 2019
NCT00155064	National Taiwan University Hospital	Hyperaldosteronism	July 2002	Phase 4
NCT01292694	Vanderbilt University\|Vanderbilt University Medical Center	Hypertension\|Pure Autonomic Failure\|Multiple System Atrophy	March 2011	Phase 1
NCT00917345	National Taiwan University Hospital\|Novartis	Primary Aldosteronism	January 2008
NCT00077064	Radiation Therapy Oncology Group\|National Cancer Institute (NCI)\|NRG Oncology	Lung Cancer\|Pulmonary Complications\|Radiation Fibrosis	June 2003	Phase 2